Document Detail


Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis.
MedLine Citation:
PMID:  2122559     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We prospectively and serially monitored plasma levels of OKT3 in 20 patients who were receiving 14- or 21-day rejection prophylaxis with OKT3. We retrospectively compared plasma OKT3 levels with biopsy scores assessed by light microscopy and immunofluorescence, clinical findings, human antimouse antibody (HAMA) production assessed by a blocking assay and by ELISA, and circulating immune complex levels assessed by a flow cytometric Raji cell assay. Using these methods, we evaluated the relationship of OKT3 sensitization, a humorally mediated immune response, to the development of vascular rejection in these patients. We found that 6 of 20 patients had declines in plasma OKT3 levels to less than 50% of their steady-state value before the conclusion of therapy (OKT3 consumption). This fall in plasma OKT3 preceded a significant rise in the CD 3 lymphocyte level by up to 3 days. All 6 patients showed HAMA production by either blocking or ELISA assay (P = less than 0.02) and developed vascular rather than cellular rejection (P = less than 0.01). OKT3 sensitization was significantly more common in patients treated with 21-day rejection prophylaxis (4 of 6 patients, P = less than 0.01). Only 4 of 14 other patients showed vascular rejection; 2 of these 4 also developed HAMA without OKT3 consumption and both had been treated with 21-day rejection prophylaxis with OKT3. None of the 20 patients showed significant levels of circulating immune complexes. This study demonstrates that OKT3 sensitization is strongly associated with vascular rejection. Vascular rejection was usually demonstrated 7 days after OKT3 consumption was seen and was coincident with HAMA production. By contrast, 4 patients without OKT3 sensitization had vascular rejection demonstrable in the early posttransplant period; in such patients, prospective immunofluorescence of biopsies was the only reliable indicator of this rejection type. The higher incidence of vascular rejection in these 20 patients was definitely related to the use of 21-day OKT3 rejection prophylaxis. Overall, 7 of the 12 patients treated with this regimen developed vascular rejection. Allograft and patient survival among patients with vascular rejection was significantly worse than in patients with cellular rejection (P = less than 0.01). Prospective monitoring of patients treated with OKT3 by serial plasma levels and by biopsy immunofluorescence will identify patients at risk for these types of humoral rejection.
Authors:
E H Hammond; C T Wittwer; J Greenwood; W A Knape; R L Yowell; R L Menlove; C Craven; D G Renlund; M R Bristow; C W DeWitt
Related Documents :
3808319 - Motor neuron disease and paraproteinemia.
2412349 - Intravenous gammaglobulin therapy in idiopathic thrombocytopenic purpura. results with ...
14989349 - Circulating ige in patients with ordinary and crusted scabies.
1483999 - Intravenous immunoglobulin therapy of immune thrombocytopenia.
6093669 - Antibodies to epstein-barr virus in patients with nasopharyngeal carcinoma and in compa...
9087159 - Clinical manifestations of ige hypogammaglobulinemia.
15269469 - Epilepsy with focal cerebral calcification: role of magnetization transfer mr imaging.
18377609 - Creatine phosphokinase values during isotretinoin treatment for acne.
12646739 - Pediatric temporal lobectomy for epilepsy.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Transplantation     Volume:  50     ISSN:  0041-1337     ISO Abbreviation:  Transplantation     Publication Date:  1990 Nov 
Date Detail:
Created Date:  1990-12-17     Completed Date:  1990-12-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  776-82     Citation Subset:  IM    
Affiliation:
Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program, Salt Lake City.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Anti-Idiotypic / analysis
Antibodies, Monoclonal / blood,  immunology,  therapeutic use*
Antigen-Antibody Complex / analysis
Graft Occlusion, Vascular
Graft Rejection / immunology*
Heart Transplantation* / mortality
Humans
Muromonab-CD3
Chemical
Reg. No./Substance:
0/Antibodies, Anti-Idiotypic; 0/Antibodies, Monoclonal; 0/Antigen-Antibody Complex; 0/Muromonab-CD3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of an 8-hour holding period on in vivo and in vitro properties of red cells and factor VIII c...
Next Document:  Synergistic immunosuppressive effects of monoclonal antibodies specific for interferon-gamma and tum...